In case you missed it: July 5 to July 9
It was a very busy week for the Contemporary OB/GYN® team.
This week’s top articles included:
Surprise bills for childbirth
In addition to welcoming a newborn, parents may be unexpectedly billed for some hospitalization services, according to a research letter in JAMA Health Forum.
Novel antifungal treatment approved for vaginal candidiasis
On June 2, 2021, ibrexafungerp (Brexafemme; Scynexis, Inc) was approved by the Food and Drug Administration for vulvovaginal candidiasis (VVC) in adult women and pediatric females who have begun menstruating. Ibrexafungerp is a triterpenoid antifungal that works by inhibiting the formation of the fungal cell wall. Ibrexafungerp (pronounced eye-BREX-ah-FUN-jerp) is the first approved drug of a novel class of antifungals.
Visual Summary: Intrahepatic Cholestasis of Pregnancy
Refer to this visual summary from SMFM wherever you practice.
Meet the Board: Yalda Afshar, MD, PhD
Introducing Contemporary OB/GYN® Editorial Advisory Board member Yalda Afshar, MD, PhD.
FDA approves Visby’s test for at-home STI identification
Published: March 28th 2025 | Updated: March 28th 2025The FDA has approved Visby Medical’s at-home sexually transmitted infection test, allowing women to screen for chlamydia, gonorrhea, and trichomoniasis without a prescription.
Read More
